KR20090052893A - 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 - Google Patents

약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 Download PDF

Info

Publication number
KR20090052893A
KR20090052893A KR1020097006944A KR20097006944A KR20090052893A KR 20090052893 A KR20090052893 A KR 20090052893A KR 1020097006944 A KR1020097006944 A KR 1020097006944A KR 20097006944 A KR20097006944 A KR 20097006944A KR 20090052893 A KR20090052893 A KR 20090052893A
Authority
KR
South Korea
Prior art keywords
growth
vancomycin
present
composition
ceftriaxone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097006944A
Other languages
English (en)
Korean (ko)
Inventor
마누 챠우드해리
Original Assignee
비너스 레머디스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비너스 레머디스 리미티드 filed Critical 비너스 레머디스 리미티드
Publication of KR20090052893A publication Critical patent/KR20090052893A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020097006944A 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법 Withdrawn KR20090052893A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN308/DEL/2005 2005-02-14
IN308DE2005 2005-02-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077012489A Division KR20070085674A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법

Publications (1)

Publication Number Publication Date
KR20090052893A true KR20090052893A (ko) 2009-05-26

Family

ID=36337659

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077012489A Ceased KR20070085674A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법
KR1020097006944A Withdrawn KR20090052893A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020077012489A Ceased KR20070085674A (ko) 2005-02-14 2006-02-08 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법

Country Status (15)

Country Link
US (2) US7960337B2 (cg-RX-API-DMAC7.html)
EP (1) EP1848413B1 (cg-RX-API-DMAC7.html)
JP (1) JP4918502B2 (cg-RX-API-DMAC7.html)
KR (2) KR20070085674A (cg-RX-API-DMAC7.html)
CN (1) CN101080221A (cg-RX-API-DMAC7.html)
AU (1) AU2006213441B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607168A2 (cg-RX-API-DMAC7.html)
CA (1) CA2597812C (cg-RX-API-DMAC7.html)
ES (1) ES2482700T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007009754A (cg-RX-API-DMAC7.html)
NZ (1) NZ555077A (cg-RX-API-DMAC7.html)
PT (1) PT1848413E (cg-RX-API-DMAC7.html)
UA (1) UA91208C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006085337A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704393B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080230A (zh) * 2005-05-13 2007-11-28 维纳斯药业有限公司 包括囊性纤维化的严重感染的治疗和控制
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
GB2459126A (en) * 2008-04-10 2009-10-14 Peter Wilson Antimicrobial agent
CA2768582C (en) * 2009-07-24 2017-02-14 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
CA2823628A1 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
ITLO20110001A1 (it) * 2011-05-03 2012-11-04 Fisiopharma Srl Flaconi di vancomicina cloroidrata con stabilità migliorata
RU2491921C1 (ru) * 2012-07-11 2013-09-10 Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" Способ лечения мастита у коров в сухостойный период
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
ES3026983T3 (en) 2013-03-15 2025-06-12 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
EP2971636A1 (en) 2013-03-15 2016-01-20 Scuderi Group, Inc. Split-cycle engines with direct injection
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
BE1021242B1 (nl) * 2014-06-11 2015-09-08 Neogen N.V. Teicoplanine lyofilisaten
CN107073072B (zh) 2014-11-06 2021-06-18 埃克斯利亚制药有限公司 糖肽组合物
DK3416669T3 (da) * 2016-02-19 2025-08-18 Klaus Brandenburg Midler og metoder til behandling af bakterielle infektioner
BR112018072948A2 (pt) 2016-05-09 2019-02-19 Xellia Pharmaceuticals Aps composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida.
CN107661470A (zh) * 2016-08-29 2018-02-06 成都特兰辰亚生物科技有限公司 添加有萘夫西林钠治疗痢疾的组合物
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US12343373B2 (en) 2020-10-30 2025-07-01 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775533A (en) * 1987-02-24 1988-10-04 Erbamont, Inc. Reconstitution of dry fill cyclophosphamide
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
GB9500978D0 (en) 1995-01-19 1995-03-08 Smithkline Beecham Plc Pharmaceutical formulations
EP0781294A1 (de) * 1995-07-17 1997-07-02 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Metallhaltige ribonukleotidpolypeptide
JP4142149B2 (ja) * 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
NZ523276A (en) * 2000-06-21 2005-02-25 Cubist Pharm Inc Compositions and methods to improve the oral absorption of antimicrobial agents
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Also Published As

Publication number Publication date
EP1848413A1 (en) 2007-10-31
MX2007009754A (es) 2007-11-07
UA91208C2 (ru) 2010-07-12
PT1848413E (pt) 2014-07-18
WO2006085337A1 (en) 2006-08-17
EP1848413B1 (en) 2014-04-09
US20080188403A1 (en) 2008-08-07
ES2482700T3 (es) 2014-08-04
JP4918502B2 (ja) 2012-04-18
NZ555077A (en) 2010-03-26
AU2006213441B2 (en) 2011-12-01
US7960337B2 (en) 2011-06-14
KR20070085674A (ko) 2007-08-27
US8778873B2 (en) 2014-07-15
ZA200704393B (en) 2008-09-25
WO2006085337B1 (en) 2006-11-02
JP2008530082A (ja) 2008-08-07
CA2597812A1 (en) 2006-08-17
AU2006213441A1 (en) 2006-08-17
BRPI0607168A2 (pt) 2009-08-11
CA2597812C (en) 2012-01-24
CN101080221A (zh) 2007-11-28
US20110257079A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
US8778873B2 (en) Parenteral combination therapy for infective conditions with drug resistant bacterium
ES2994966T3 (en) Single doses of oritavancin for treating or preventing a bacterial infection
KR100900208B1 (ko) 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물
JP2008540515A (ja) 嚢胞性線維症を含む重症感染症の処置および管理
WO2013042140A2 (en) Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
RU2521391C2 (ru) Новые однократные единичные составы карбапенема и аминогликозида
JP6552648B2 (ja) 抗菌組成物
US20240131034A1 (en) Methods of treating staphylococcus aureus bacteremia infections
Pacifici Clinical pharmacology of tigecycline in children
Pezzani Cefuroxime
Eichenwald Antimicrobial therapy in children
Das Antibacterial Antibiotics in General Practice

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090403

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid